1. Amelioration of pancreatic fat accumulation in Japanese type 2 diabetes patients treated with sodium‐glucose cotransporter 2 inhibitors: a retrospective study
- Author
-
Ayumi Tokunaga, Shingo Fujita, Yoshiya Hosokawa, Yukari Fujita, Kenji Fukui, Takekazu Kimura, Iichiro Shimomura, Tomomi Horii, and Junji Kozawa
- Subjects
0301 basic medicine ,medicine.medical_specialty ,Short Communication ,Endocrinology, Diabetes and Metabolism ,030209 endocrinology & metabolism ,Type 2 diabetes ,Gastroenterology ,03 medical and health sciences ,0302 clinical medicine ,Fat accumulation ,Internal medicine ,Hounsfield scale ,medicine ,In patient ,terms: type 2 diabetes ,030109 nutrition & dietetics ,Nutrition and Dietetics ,business.industry ,pancreatic fat ,Fatty liver ,Retrospective cohort study ,medicine.disease ,RC31-1245 ,medicine.anatomical_structure ,Sodium/Glucose Cotransporter 2 ,Pancreas ,business ,SGLT‐2 inhibitor - Abstract
Background Prior reports have suggested that pancreatic fat is related to type 2 diabetes. Sodium‐glucose co‐transporter‐2 (SGLT‐2) inhibitors are expected to reduce ectopic fat accumulation. Aim This study assessed the effect of SGLT‐2 inhibitors on pancreatic and liver fat accumulations in patients with type 2 diabetes. Materials and Methods Retrospective analyses of indices of pancreatic and liver fat accumulations were conducted in 22 type 2 diabetes outpatients who were receiving SGLT‐2 inhibitors for more than 12 weeks. The differences between the pancreatic (P) or liver (L) and splenic (S) computed tomography values were evaluated. Results Fatty pancreas was defined as P−S
- Published
- 2021
- Full Text
- View/download PDF